Poinsettia Pharmaceutical Montelukast Sodium Granules Approval for Marketing Approval

Medical Network News, March 31, recently, Guangzhou Poinsettia Pharmaceutical's Montelukast Sodium Granules 4 generic listing applications have entered the "under review" status.
According to data from Minai.
com, in 2019, at the terminals of Chinese public medical institutions and physical pharmacies in Chinese cities, the total sales of montelukast has risen to 3.
5 billion yuan, and montelukast sodium tablets have been included in the first batch of national sources.
Tablets and granules are included in the third batch of national sourcing, and how the poinsettia will be deployed in the market after approval is worthy of attention.

 

Figure 1: The situation of products that will be approved

Source: NMPA official website

 

Figure 2: Sales of montelukast

Source: Minet database

 

Montelukast is a commonly used drug for the treatment of asthma and allergic rhinitis.
According to data from Minei, in 2019, in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminals and Chinese urban physical pharmacies , the total sales of montelukast has risen to 3.
5 billion yuan, of which the terminal of public medical institutions in China is the main battlefield, and the proportion of granules is about 10%, and the proportion of terminal granules in Chinese urban physical pharmacies is about 4%.
The potential is yet to be developed.

 

Figure 3: Enterprise competition of 2020E montelukast sodium granules in the retail market

Source: Mi Nei.
com, the competitive landscape of physical pharmacies in cities in China

 

Montelukast sodium granules were included in the third batch of national procurement.
Three domestic pharmaceutical companies, Jiangsu Zhengda Fenghai Pharmaceutical, Jiangsu Wusongjiang Pharmaceutical, and Changchun Haiyue Pharmaceutical, won the bid.
The original research company Merck & Co.
, Ltd.
failed.
The decline in the share of the original research companies of institutional terminals is a high probability event.
In the physical pharmacy terminal of Chinese cities, the sales of montelukast sodium granules originally developed have a rapid upward trend.
The growth rate from 2018 to 2019 is 245.
54% and 33.
76%.
It is also expected to have positive growth in 2020.
Will Merck accelerate its layout The retail market remains to be seen.
Can't keep up with the poinsettia pharmnet.
com.
cn/news/yyzb/" target="_blank">bidding by the State pharmnet.
com.
cn/news/yyzb/" target="_blank">Procurement , will it focus its firepower on the retail market in the future and compete with Merck? Meinenet will continue to follow up the report.

 

　　Source: Listed company announcements, Minet database

　　Medical Network News, March 31, recently, Guangzhou Poinsettia Pharmaceutical's Montelukast Sodium Granules 4 generic listing applications have entered the "under review" status.
According to data from Minai.
com, in 2019, at the terminals of Chinese public medical institutions and physical pharmacies in Chinese cities, the total sales of montelukast has risen to 3.
5 billion yuan, and montelukast sodium tablets have been included in the first batch of national sources.
Tablets and granules are included in the third batch of national sourcing, and how the poinsettia will be deployed in the market after approval is worthy of attention.

 

　　Figure 1: The situation of products that will be approved

　　Source: NMPA official website

 

　　Figure 2: Sales of montelukast

　　Source: Minet database

 

　　Montelukast is a commonly used drug for the treatment of asthma and allergic rhinitis.
According to data from Minei, in 2019, in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminals and Chinese urban physical pharmacies , the total sales of montelukast has risen to 3.
5 billion yuan, of which the terminal of public medical institutions in China is the main battlefield, and the proportion of granules is about 10%, and the proportion of terminal granules in Chinese urban physical pharmacies is about 4%.
The potential is yet to be developed.

 

　　Figure 3: Enterprise competition of 2020E montelukast sodium granules in the retail market

　　Source: Mi Nei.
com, the competitive landscape of physical pharmacies in cities in China

 

　　Montelukast sodium granules were included in the third batch of national procurement.
Three domestic pharmaceutical companies, Jiangsu Zhengda Fenghai Pharmaceutical, Jiangsu Wusongjiang Pharmaceutical, and Changchun Haiyue Pharmaceutical, won the bid.
The original research company Merck & Co.
, Ltd.
failed.
The decline in the share of the original research companies of institutional terminals is a high probability event.
In the physical pharmacy terminal of Chinese cities, the sales of montelukast sodium granules originally developed have a rapid upward trend.
The growth rate from 2018 to 2019 is 245.
54% and 33.
76%.
It is also expected to have positive growth in 2020.
Will Merck accelerate its layout The retail market remains to be seen.
Can't keep up with the poinsettia pharmnet.
com.
cn/news/yyzb/" target="_blank">bidding by the State pharmnet.
com.
cn/news/yyzb/" target="_blank">Procurement , will it focus its firepower on the retail market in the future and compete with Merck? Meinenet will continue to follow up the report.

 

　　Source: Listed company announcements, Minet database